Last reviewed 2026-04-23 · How we verify

additional pvb (ropivacaine)

Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.

Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials. Used for Local anesthesia via paravertebral block (Phase 3 investigational use).

At a glance

Mechanism of action

Ropivacaine is an amide-type local anesthetic that reversibly inhibits sodium influx into nerve fibers, thereby blocking the generation and conduction of nerve impulses. This mechanism produces local anesthesia and analgesia in the area of administration. The 'additional PVB' designation suggests this is a study of ropivacaine administered via paravertebral block, a regional anesthesia technique.

Approved indications

• Local anesthesia via paravertebral block (Phase 3 investigational use)

Common side effects

• Transient neurological symptoms
• Hypotension
• Bradycardia
• Nausea
• Systemic toxicity (at high doses)

Key clinical trials

• Thoracic Paravertebral Block for Postoperative Analgesia After Video-assisted Thoracic Surgery. (PHASE3)
• Optimal Postoperative Chest Tube and Pain Management in Patients Surgically Treated for Primary Spontaneous Pneumothorax (Pneumotrial) (NA)
• Enhanced Recovery After Urologic Surgery (NA)
• Optimal Postoperative Pain Management After Lung Surgery (OPtriAL) (NA)
• PEF-Block & Ribs Fractures (NA)
• Paravertebral Block for Proximal Humeral Fracture Surgery (NA)
• Ultrasound-Assisted Paravertebral Block v. Traditional Paravertebral Block For Pain Control (NA)
• TAVI Protocol - Paravertebral Block Study (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.